Miquel Granell

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

Laura Rosiñol, Albert Oriol, Ana Isabel Teruel et al. · Blood · 2012 · 485 citations · Full text

Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial

Meletios Α. Dimopoulos, Judith Trotman, Alessandra Tedeschi et al. · The Lancet Oncology · 2016 · 231 citations

Open-label Substudy, Immunology, Clinical Trials +4

Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · Blood · 2012 · 143 citations · Full text

Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition

Miquel Granell, Xavier Calvo, Antoni García‐Guiñón et al. · Haematologica · 2017 · 123 citations · Full text

GEM2005 trial update comparing VMP/VTP as induction in elderly multiple myeloma patients: do we still need alkylators?

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · Blood · 2014 · 102 citations · Full text